ABSTRACT
INTRODUCTION: Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. PATIENTS AND METHODS: This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies. RESULTS: A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml. CONCLUSION: The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.
Subject(s)
Colorectal Neoplasms/drug therapy , Nomograms , Pyrrolidines/therapeutic use , Trifluridine/therapeutic use , Uracil/analogs & derivatives , Adult , Aged , Aged, 80 and over , Colorectal Neoplasms/pathology , Drug Combinations , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/etiology , Female , Humans , Male , Middle Aged , Neoplasm Metastasis , Prognosis , Progression-Free Survival , Pyrrolidines/adverse effects , Response Evaluation Criteria in Solid Tumors , Retrospective Studies , Spain , Survival Rate , Thymine , Trifluridine/adverse effects , Uracil/adverse effects , Uracil/therapeutic useABSTRACT
Megestrol acetate is a synthetic progestin that has been used since the 1970s for the treatment of advanced cancer and subsequently to treat anorexia, cachexia and weight loss in AIDS patients. It has been shown that high doses or prolonged treatment with this drug may cause Cushing's syndrome, new-onset diabetes and suppression of plasma ACTH and cortisol levels. Megestrol acetate may cause suppression of the pituitary-adrenal axis due to the affinity of this compound for the glucocorticoid receptor. Recognising the glucocorticoid-like activity of megestrol and its effects at the axis level is important for the diagnosis of sub-clinical adrenal insufficiency. We present the case of a 74-year-old woman with infiltrating ductal breast carcinoma refractory to prolonged hormonal treatment with megestrol acetate, presenting with adrenal insufficiency (AU)
No disponible
Subject(s)
Humans , Male , Aged , Adrenal Insufficiency/chemically induced , Adrenal Insufficiency/physiopathology , Antineoplastic Agents, Hormonal/adverse effects , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Megestrol Acetate/adverse effects , Pericardial Effusion/complications , Pericardial Effusion/etiology , Pericardial Effusion/surgeryABSTRACT
No disponible
